Reference number(s)
2103-H

SPECIALTY QUANTITY LIMIT PROGRAM

KISQALI FEMARA CO-PACK (ribociclib tablets; letrozole tablets)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Kisqali Femara Co-pack 600mg daily dose (packaged as Kisqali [ribociclib] 200 mg tablets and Femara [letrozole] 2.5mg tablets)	91 tablets (63 Kisqali tablets + 28 Femara tablets) per 28 days	Recommended starting dose for Kisqali Femara Co-pack: • Kisqali: 600mg orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. • Femara: 2.5mg orally once daily throughout the 28-day cycle. Dose modifications for adverse reactions: • First dose reduction: Kisqali 400mg/day for 21 consecutive days and Femara 2.5mg/day throughout the 28-day cycle. • Second dose reduction: Kisqali 200mg/day for 21 consecutive days and Femara 2.5mg/day throughout the 28-day cycle.
Kisqali Femara Co-pack 400mg daily dose (packaged as Kisqali [ribociclib] 200 mg tablets and Femara [letrozole] 2.5mg tablets)	70 tablets (42 Kisqali tablets + 28 Femara tablets) per 28 days	
Kisqali Femara Co-pack 200mg daily dose (packaged as Kisqali [ribociclib] 200 mg tablets and Femara [letrozole] 2.5mg tablets)	49 tablets (21 Kisqali tablets + 28 Femara tablets) per 28 days	

III. REFERENCE

1. Kisqali Femara Co-Pack [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2019.

CVS caremark™